OS Therapies (OSTX) announced it has entered into an asset purchase agreement to acquire the listeria monocytogenes-based immuno-oncology programs and related intellectual property assets from Ayala ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback